We have recently reported a long noncoding RNA that interacts with nuclear factor κB (NFκB) and represses NFκB activation by physically masking the phosphorylation site of inhibitor of NFκB (IκB). Our findings have revealed a new class of long noncoding RNAs (lncRNAs) that directly interact with proteins involved in signal transduction pathways and interfere with cell signaling. This implicates a potential strategy for the design of RNA-based targeted drugs.
Keywords: Cancer; NFκB; long noncoding RNA; signal pathway; targeted therapy.